As a result of the screening in collaboration with several pharmaceutical companies, we found several potent compounds, including a novel MEK inhibitor trametinib by screening for p15 inducers
As a result of the screening in collaboration with several pharmaceutical companies, we found several potent compounds, including a novel MEK inhibitor trametinib by screening for p15 inducers.36 After submitting the patent, trametinib was in\licensed by GlaxoSmithKline (GSK) in 2006 and clinically developed. the quantitative abnormalities in gene expression with carcinogenesis, and discuss the importance…